Bayer gets FDA priority review for blood cancer drug

FRANKFURT, Germany (Reuters) – German drugmaker Bayer won the U.S. Food and Drug Administration’s priority review status for an experimental drug for a difficult to treat type of blood cancer, bolstering its development pipeline.


Reuters: Health News

Leave a Reply

Your email address will not be published. Required fields are marked *

captcha

Please enter the CAPTCHA text